https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2020-04-22 / Curr. Opin. Biotechnol. 2020 Apr;65:190-196
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2020-04-22 / Curr. Opin. Biotechnol. 2020 Apr;65:190-1962020-04-22 00:00:002020-04-22 00:00:00Are dendritic cells the most appropriate therapeutic vaccine for patients with ovarian cancer?
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2020-04-21 / J Transl Med 2020 04;18(1):176
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2020-04-21 / J Transl Med 2020 04;18(1):1762020-04-21 00:00:002021-05-19 12:39:42Cytokine network analysis of immune responses before and after autologous dendritic cell and tumor cell vaccine immunotherapies in a randomized trial
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2020-04-19 / Phytother Res 2020 Apr;
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2020-04-19 / Phytother Res 2020 Apr;2020-04-19 00:00:002020-04-19 00:00:00Curcumin effect on cancer cells‘ multidrug resistance: An update
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2020-04-18 / Phytomedicine 2020 Apr;70:153218
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2020-04-18 / Phytomedicine 2020 Apr;70:1532182020-04-18 00:00:002020-04-18 00:00:00Efficacy and safety of curcumin in combination with paclitaxel in patients with advanced, metastatic breast cancer: A comparative, randomized, double-blind, placebo-controlled clinical trial
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2020-04-07 / Clin Transl Oncol 2020 Apr;
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2020-04-07 / Clin Transl Oncol 2020 Apr;2020-04-07 00:00:002020-04-07 00:00:00Cellular immunotherapy: a clinical state-of-the-art of a new paradigm for cancer treatment
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2020-04-02 / Adv Drug Deliv Rev 2020;163-164:145-156
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2020-04-02 / Adv Drug Deliv Rev 2020;163-164:145-1562020-04-02 00:00:002020-04-02 00:00:00A moderate thermal dose is sufficient for effective free and TSL based thermochemotherapy
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2020-04-01 / J Immunother Cancer 2020 Apr;8(1)
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2020-04-01 / J Immunother Cancer 2020 Apr;8(1)2020-04-01 00:00:002020-04-01 00:00:00Vaccine efficacy against primary and metastatic cancer with in vitro-generated CD103 conventional dendritic cells
